Blockchain Registration Transaction Record

NRx Pharma Advances Dual Preservative-Free Ketamine Therapies

NRx Pharmaceuticals advances dual preservative-free ketamine therapies KETAFREE™ and NRX-100 after FDA approval to remove neurotoxic preservative BZT from formulations.

This development matters because it addresses critical safety concerns in ketamine therapy while expanding treatment options for severe mental health conditions. The elimination of benzethonium chloride (BZT) preservative could reduce neurotoxicity risks associated with current ketamine formulations, potentially making treatment safer for patients with treatment-resistant depression, bipolar disorder, and suicidal ideation. Given the growing mental health crisis and the limitations of existing antidepressants, improved ketamine therapies could provide life-saving alternatives for patients who haven't responded to conventional treatments. The dual regulatory approach also demonstrates pharmaceutical innovation in bringing safer medications to market more efficiently.